



**CHANGE OF CONTENT OF PRICE INQUIRY NO. NUSI/74/PR69771-69922-699224/2024  
as of 25.07.2024.**

**Subject:** Project pn . "Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Pharmaceutical Plant Polpharma S.A.,  
Subject of purchase - **purchase and delivery of raw materials used in the synthesis of oligonucleotides.**

The ordering party informs that **on 31.07.2024 revised the content of the price inquiry to the following extent:**

Description before change	Description after the change
<b>III. DESCRIPTION OF THE SUBJECT OF THE INQUIRY</b>	
<b>1.PART 1 - DMT-2'-O-MOE-A(Bz)-CE Phosphoramidite</b> , CAS 616-47-7, Purity: 31PNMR - NLT 98.0%, Purity: RP-HPLC - NLT 98.0%, Residual solvent content - NLT 3.0%, Moisture content - NLT 0.30%, quantity 900 g	<b>1.PART 1 - DMT-2'-O-MOE-A(Bz)-CE Phosphoramidite</b> , <b>CAS 251647-53-7</b> , Purity: 31PNMR - NLT 98.0%, Purity: RP-HPLC - NLT 98.0%, Residual solvent content - NLT 3.0%, Moisture content - NLT 0.30%, quantity 900 g
Description before change	Description after the change
<b>VIII. PLACE AND DEADLINE FOR SUBMISSION OF BIDS</b>	
<b>8.1</b> Bids shall be submitted by the deadline of <b>01/08/2024</b> electronically to: <a href="mailto:barbara.wendolowska@polpharma.com">barbara.wendolowska@polpharma.com</a> in the form of electronically signed documents or scans of documents.	<b>8.1</b> Bids shall be submitted by the deadline of <b>05/08/2024</b> electronically to: <a href="mailto:barbara.wendolowska@polpharma.com">barbara.wendolowska@polpharma.com</a> in the form of electronically signed documents or scans of documents.